• Thurs news: AbbVie Parkinson’s drug. Arch raises $3B biotech fund. Biogen dropping failed Sage tremor drug. AZ gets sought-after Tagrisso OK. Pfizer withdrawing sickle cell med. See more on our front page

karuna deal


<















































You don't know what you are talking about. Celgene people got fucking massive retention bonuses and some of these shit for brains still work at BMS. I guess you didn't make the cut...

They got massive retention bonuses and two more years of Celgene stock award levels. Floodgates opened last year and they've been exiting in droves.
 




Who exactly at BMS is going to be reviewing the "quality talent"???? The only talent they have are the field reps but they for some reason keep getting cut. Let's look at middle management, RMKs. The Org chart is quite deep with crap. Field sales should review top talent. They are the only ones that know how to sell anyway, and they actually understand the business